Valuation: Biocorrx Inc

Market Cap 98.79L 86.41L 79.68L 73.66L 1.4Cr 94Cr 1.42Cr 9.53Cr 3.74Cr 46Cr 3.71Cr 3.63Cr 160.4Cr P/E 2024
-0.78x
P/E 2025 -1.56x
Enterprise Value 1.19Cr 1.04Cr 95.83L 88.58L 1.68Cr 113.31Cr 1.71Cr 11Cr 4.49Cr 56Cr 4.46Cr 4.36Cr 192.89Cr EV / Sales 2024
1,004x
EV / Sales 2025 11.4x
Free-Float
38.64%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 58 09/11/2020
President 77 05/01/2024
Director TitleAgeSince
Director/Board Member 58 07/03/2013
Chairman 57 -
Director/Board Member 77 01/03/2019
Change 5-day change 1-year change 3-year change Capi.($)
-15.84%+6.09% - - 1.16Cr
-1.59%-1.91%+53.59%+48.63% 13TCr
-0.39%+4.01%+8.32%+40.32% 9.11TCr
-0.42%+2.90%+0.55%+71.35% 2.72TCr
-0.08%-3.69%+20.61%+49.68% 2.3TCr
-1.75%-1.11%-20.93%-25.61% 2.03TCr
+0.25%+8.14%+19.94%+158.27% 1.78TCr
-0.54%+0.64%+59.58%+120.89% 1.48TCr
+3.14%-1.07%+3.29%+10.78% 1.45TCr
-0.38%+4.37%-11.32%-2.43% 1.29TCr
Average -1.56%+1.73%+14.85%+52.43% 3.94TCr
Weighted average by Cap. +0.02%+1.58%+25.66%+49.18%

Financials

2024 2025
Net sales 7.66T 6.7T 6.18T 5.72T 10.86T 7L 11.04T 73.97T 29T 4L 28.78T 28.15T 12.45L 8L 7L 6L 6L 11.3L 7.6Cr 11.49L 76.94L 30.16L 3.74Cr 29.93L 29.28L 13Cr
Net income -51.06L -44.66L -41.19L -38.07L -72.35L -49Cr -73.57L -4.93Cr -1.93Cr -24Cr -1.92Cr -1.88Cr -83Cr -34.4L -30.09L -27.75L -25.65L -48.74L -33Cr -49.57L -3.32Cr -1.3Cr -16Cr -1.29Cr -1.26Cr -56Cr
Net Debt 27.18L 23.78L 21.93L 20.27L 38.52L 26Cr 39.17L 2.62Cr 1.03Cr 13Cr 1.02Cr 99.84L 44Cr 20.01L 17.51L 16.14L 14.92L 28.36L 19Cr 28.84L 1.93Cr 75.72L 9.39Cr 75.13L 73.51L 32Cr
Logo Biocorrx Inc
BioCorRx Inc. is an addiction treatment solutions company. The Company is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. It also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. It is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.
Employees
-